Nivolumab for NSCLC: five years on

Prof Brahmer presents data at AACR 2017 from a five year follow up of patients with non-small cell lung cancer treated with nivolumab. Prof Brahmer spoke with ecancer about these results here, and slides from this presentation are available here.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o5FBtB
via IFTTT